S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Bonus episode: Alternatives to hysterectomy & uterine-preserving options for fibroids, part 2
December 22nd 2022This is part 2 of a 2-part series. In this bonus episode of Pap Talk, get an exclusive recap of Kimberly Kho, MD's presentation from AAGL 2022 on alternatives to hysterectomy and uterine-preserving options for fibroids.
Listen
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More
Bonus episode: Alternatives to hysterectomy & uterine-preserving options for fibroids, part 1
December 21st 2022This is part 1 of a 2-part series. In this bonus episode of Pap Talk, get an exclusive recap of Kimberly Kho, MD's presentation from AAGL 2022 on alternatives to hysterectomy and uterine-preserving options for fibroids.
Listen
